Without an adequate intake of these nutrients, glutathione production is limited, and our bodys antioxidant capacity decreases
EASD 2023 for CT-388) and plotted them on a log-scale scatter
Looking at the pipelines set out by major manufacturers, The Pharmaceutical Journal highlights some of the most promising and most novel approaches that could be rolled out to patients in the years to come, unpacking how they work and what benefits they could offer
Retatrutide activates GLP-1, GIP, and glucagon receptors, influencing appetite regulation, insulin signaling, and energy expenditure simultaneously

Referencias: The public's use and views of GLP-1 drugs, KFF Health Tracking Poll, 2024 Anti-obesity drug market to reach USD 82.55 billion in 2031, exclusive report by coherent market insights, 2025 Why are we still in need for novel anti-obesity medications?, The Lancet Regional Health - Europe, 2024 Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine, 2021 High protein intake stimulates postprandial GLP1 and PYY release, PubMed, 2013 Closing Americas fiber intake gap, PubMed, 2016 Recent achievements and future directions of anti-obesity medications, The Lancet Regional Health - Europe, 2024 Resistant starch intake facilitates weight loss in humans by reshaping the gut microbiota, Nature Metabolism, 2024 GLP-1 Receptor agonists significantly impair taste function, Science Direct, 2025 Real-world insights into incretin-based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross-sectional study, National Library of Medicine, 2025 Las marcas y logotipos INGREDION, VITESSENCE y HOMECRAFT son marcas registradas del grupo de empresas Ingredion
